EARLY LONGITUDINAL IMAGING IN A PARKINSON’S PROGRESSION MARKERS INITIATIVE (PPMI)

The PPMI study is launching a new 18 month sub-study evaluating the imaging characteristics of two scans, DaTscan and AV-133 imaging, in newly diagnosed Parkinson’s disease (PD) patients.

WHO QUALIFIES?

- Individuals who have been diagnosed with PD within 2 years of screening.
- Diagnosed at age 30 or older.
- Not currently taking PD medications.

WHAT’S INVOLVED?

- A screening visit, and three additional visits at 6-month intervals.
- Participants for this study will undergo medical scans, a blood draw, and various cognitive and motor examinations, during screening and each study visit.
- Participants will be compensated for each study visit.

WHAT ARE THE GOALS?

- To determine the longitudinal change of AV-133 and DaTscan imaging in newly untreated PD subjects.
- To evaluate the correlation between the long-term change of imaging outcomes and other PD clinical symptoms and blood biomarkers.
- To establish whether short-term imaging outcomes predict long-term disease progression.

Interested?
Contact Raymond James at 617-638-7745, or rcjames@bu.edu